Literature DB >> 19467327

Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials.

Laura C Amann1, Tobias B Halene, Richard S Ehrlichman, Stephen N Luminais, Nan Ma, Ted Abel, Steven J Siegel.   

Abstract

Ketamine is an NMDA receptor antagonist with a variety of uses, ranging from recreational drug to pediatric anesthetic and chronic pain reliever. Despite its value in the clinical setting, little is known about the immediate and long-lasting effects of repeated ketamine treatment. We assessed the effects of chronic administration of a subanesthetic dose of ketamine on contextual fear conditioning, detection of pitch deviants and auditory gating. After four, but not two, weeks of daily ketamine injections, mice exhibited decreased freezing in the fear conditioning paradigm. Gating of the P80 component of auditory evoked potentials was also significantly altered by treatment condition, as ketamine caused a significant decrease in S1 amplitude. Additionally, P20 latency was significantly increased as a result of ketamine treatment. Though no interactions were found involving test week, stimulus and treatment condition, these results suggest that repeated ketamine administration impairs fear memory and has lasting effects on encoding of sensory stimuli.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467327      PMCID: PMC2726963          DOI: 10.1016/j.nbd.2009.05.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  64 in total

1.  Ketamine administration disturbs behavioural and distributed neural correlates of fear conditioning in the rat.

Authors:  Charmaine Y Pietersen; Fokko J Bosker; Folkert Postema; Dirk S Fokkema; Jakob Korf; Johan A den Boer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-04-19       Impact factor: 5.067

2.  The role of dorsal hippocampus and basolateral amygdala NMDA receptors in the acquisition and retrieval of context and contextual fear memories.

Authors:  Patricia Matus-Amat; Emily A Higgins; David Sprunger; Karli Wright-Hardesty; Jerry W Rudy
Journal:  Behav Neurosci       Date:  2007-08       Impact factor: 1.912

3.  Contributions of the retrosplenial and posterior parietal cortices to cue-specific and contextual fear conditioning.

Authors:  Christopher S Keene; David J Bucci
Journal:  Behav Neurosci       Date:  2008-02       Impact factor: 1.912

4.  Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice?

Authors:  D Umbricht; D Vyssotki; A Latanov; R Nitsch; H-P Lipp
Journal:  Clin Neurophysiol       Date:  2005-02       Impact factor: 3.708

5.  Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.

Authors:  S J Siegel; C R Maxwell; S Majumdar; D F Trief; C Lerman; R E Gur; S J Kanes; Y Liang
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

6.  An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition.

Authors:  Jacob C Ong; Suzanne A Brody; Charles H Large; Mark A Geyer
Journal:  J Pharmacol Exp Ther       Date:  2005-08-25       Impact factor: 4.030

7.  Side effects of ketamine in the long-term treatment of neuropathic pain.

Authors:  Petr Cvrcek
Journal:  Pain Med       Date:  2008-03       Impact factor: 3.750

8.  Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study.

Authors:  Celia J A Morgan; Ali Mofeez; Brigita Brandner; Lesley Bromley; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

Review 9.  Ketamine.

Authors:  B Sinner; B M Graf
Journal:  Handb Exp Pharmacol       Date:  2008

10.  An animal model of emotional blunting in schizophrenia.

Authors:  Charmaine Y Pietersen; Fokko J Bosker; Janine Doorduin; Minke E Jongsma; Folkert Postema; Joseph V Haas; Michael P Johnson; Tineke Koch; Tony Vladusich; Johan A den Boer
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

View more
  16 in total

1.  NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia.

Authors:  John A Saunders; Michael J Gandal; Steve J Siegel
Journal:  Neurobiol Dis       Date:  2012-01-09       Impact factor: 5.996

Review 2.  How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.

Authors:  Xin Wang; António Pinto-Duarte; Terrence J Sejnowski; M Margarita Behrens
Journal:  Antioxid Redox Signal       Date:  2012-10-18       Impact factor: 8.401

3.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

4.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853

5.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

Review 6.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

7.  Prediction of individual differences in fear response by novelty seeking, and disruption of contextual fear memory reconsolidation by ketamine.

Authors:  Florian Duclot; Iara Perez-Taboada; Katherine N Wright; Mohamed Kabbaj
Journal:  Neuropharmacology       Date:  2016-06-22       Impact factor: 5.250

8.  The electrophysiological signature of motivational salience in mice and implications for schizophrenia.

Authors:  Carolin Moessnang; Ute Habel; Frank Schneider; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2012-08-22       Impact factor: 7.853

9.  Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine.

Authors:  L Elliot Hong; Ann Summerfelt; Robert W Buchanan; Patricio O'Donnell; Gunvant K Thaker; Martin A Weiler; Adrienne C Lahti
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

10.  Deficits in emotional learning and memory in an animal model of schizophrenia.

Authors:  Monica M Bolton; Chelcie F Heaney; Jonathan J Sabbagh; Andrew S Murtishaw; Christy M Magcalas; Jefferson W Kinney
Journal:  Behav Brain Res       Date:  2012-05-05       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.